This year, AI dominated the conversation at the World Economic Forum. Satya Nadella and I weighed in. Â
Â
During our panel moderated by Peter Lee, Satya and I discussed what AI has already unlocked for the biopharmaceutical industry—and the emerging opportunities on the horizon. Â
Â
We’re already seeing the promising results of large language models when it comes to operational areas of our industry. Microsoft has partnered with Novartis to develop proprietary applications that will help us do better, faster. And because many of the core processes within our R&D will be massively accelerated by these targeted applications of GenAI, we will hopefully be able to bring medicines to patients at a quicker pace than ever before. That all said, it’s important to note: we think about AI as a copilot – not something functioning totally on its own, or replacing our people.Â
Â
In the years to come, there’s potential for AI to help us design better drugs. With generative chemistry, something we’ve been working on closely with Microsoft over the past few years, we’re already identifying ways to build target molecules for new medicines faster. And with every additional discovery, we’re closer to unlocking the wonders of the human body—sifting through the 40 trillion cells that have evolved over the past 2 million years (but, even with all the hype, this is still a ways out). Â
Â
If you’re looking for something to read on the subject – check out Peter’s book: The AI Revolution in Medicine: GPT-4 and Beyond by Peter Lee, Carey Goldberg, and Issac Kohane. As an exploration of the impact of AI on medicine and the avenues and limitations of the technology, it’s a good choice for those in our industry who are eager to learn more about where this moment in health and tech could take us—and where we need to remain humble on the journey. #wef24